Search News Archives
Follow us on
Conferences | Events
Lab Bulletin Media Partners
Biofocus DPI

Biofocus DPI

Biofocus DPI

Products

Contact Biofocus DPI


If you have not logged into the website then please enter your details below.

All articles from Biofocus DPI

  BioFocus enters collaboration with Michael J. Fox Foundation BiofocusBioFocus announced today that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson's Research, a not-for-profit organization focused on developing therapies for Parkinson's disease. Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs, to identify compounds that have the basis for a novel Parkinson's disease diagnostic test...

 

  BioFocus extends collaboration with Usher III Initiative BiofocusBioFocus has announced that it has expanded a collaboration with the Usher III Initiative, Inc., a non-profit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision...

 

  Astellas Pharma and BioFocus sign target discovery agreement BiofocusBioFocus announced today that it has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders. Under the agreement, BioFocus will utilize its SilenceSelect® target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration...

 

  University of Nottingham and BioFocus sign compound management agreement BiofocusBioFocus announced today that its Compound Focus, Inc. subsidiary has signed a compound management services agreement with the University of Nottingham, UK. Under the terms of this agreement, Compound Focus will select, source, acquire, perform quality control checks and reformat a compound collection before returning to the Managed Chemical Compound Collection (MCCC) at the University of Nottingham...

 

  BioFocus leads compound library market with innovative business model BiofocusBioFocus announced today that it has established an innovative and unique model for the sale of its SoftFocus compound libraries. Going forward, BioFocus will provide a limited number of clients with SoftFocus libraries on a subscription basis only. These libraries are designed to target protein families of particular interest to the subscribers. This shared exclusivity model will allow clients access to high value, novel compounds with limited competition on derived intellectual property...

 

  BioFocus and Almac collaborate to offer fluorescent lifetime assays BiofocusBioFocus have announced that it has entered into collaboration with Almac allowing BioFocus customers with compound screening and profiling requirements to access Almac's FLEXYTETM fluorescence lifetime (FLT) assays. Integrating the assay technology allows BioFocus to offer an FLT platform that will complement its current target class capabilities, provide access to previously inaccessible epigenetic targets and offer alternative approaches to fragment-based screens and kinetic profiling...

 

  Lundbeck Research USA, Inc. and BioFocus sign compound management agreement BiofocusBioFocus announced today that its Compound Focus, Inc. subsidiary has signed a three-year compound management services agreement with Lundbeck Research USA, Inc. Under the terms of this agreement, Compound Focus will manage Lundbeck's liquid chemical library collection, distributing screening sets to high throughput screening centers in both the USA and Europe

 

  Ono and Galapagos subsidiary BioFocus sign target discovery agreement in the field of autoimmune disease BiofocusOno Pharmaceutical Co., Ltd. (Osaka, Japan) and BioFocus (Saffron Walden, UK) announced today that they have signed a collaboration agreement, focused on discovering novel targets in the field of autoimmune disease. Under the agreement, BioFocus will receive research funding and success payments based on the progress of the collaboration. BioFocus will utilize its unique SilenceSelect® target discovery platform to deliver validated targets for Ono's immunology programs. Ono aims to find modulators for these targets and generate novel and innovative drug candidates.

 

  BioFocus extends collaboration with Amgen into 2012 BiofocusBioFocus announced today that it has extended its contract with Amgen for 2011 and 2012, with an expansion to include target discovery and validation services. Under the terms of the extended agreement, BioFocus will receive €2.0 M ($2.6 M) in research fees for the first year. Additionally, BioFocus is eligible to receive payments of access fees and success-based milestones

 

  BioFocus extends collaboration with Chiesi BioFocus, a leading provider of integrated gene-to-clinical candidate drug discovery services, announced today that it has expanded a collaboration with Chiesi Farmaceutici, a privately held Italian pharmaceutical company. Total value for the collaboration with Chiesi has now reached €2.5 million.

 

  BioFocus and the National Cancer Institute sign compound management agreement BioFocus announced today that its Compound Focus subsidiary has signed an agreement with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH). Under the terms of the agreement, BioFocus will provide compound management services to NCI for a base period of three years for a total of up to $5 million (€3.7 M), with two one-year extension options.

 

  BioFocus signs compound management agreement with eMolecules, Inc. BioFocus, a leading provider of integrated gene-to-clinical candidate drug discovery services and eMolecules, Inc., the creators of the open-access chemical structure search engine, today announced that they have signed a compound management service agreement. Under the agreement eMolecules has selected Compound Focus, Inc., the BioFocus compound management operation located in South San Francisco, as its preferred partner for client compound order aggregation services.

 

  BioFocus launches new compound libraries BioFocus, a leading provider of integrated gene-to-clinical candidate drug discovery services, today announced the launch of two new compound libraries, targeting Family C GPCR's and protein-protein interactions.

 

  Argenta expands collaboration with Genentech to include BioFocus Argenta, a service division of Galapagos NV (Euronext: GLPG), announced today it has signed a contract extension with Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). The extended agreement expands the portfolio of projects which are in collaboration with Genentech and allows Genentech to place projects directly into Galapagos' other service division, BioFocus.

 

  BioFocus and Usher III Initiative, Inc. announce collaboration BioFocus and the Usher III Initiative, Inc., a not-for-profit organization, announced today that they have embarked on a drug discovery project focused on Usher Syndrome Type III. Usher Syndrome is a rare genetic disorder that causes the loss of hearing and vision. Under the agreement, BioFocus will perform an integrated program encompassing medicinal chemistry and biological sciences.

 

  BioFocus and University of Bristol enter drug discovery collaboration in chronic pain BioFocus and the University of Bristol today announced a new drug discovery collaboration aimed at developing treatments for chronic pain associated with diabetes (diabetic neuropathic pain). BioFocus will provide hit-to-lead and lead optimization services for a Wellcome Trust funded program at the University of Bristol. Total contract value for BioFocus could exceed €3.3 million in research fees over two years.

 

  NIH extends agreement with BioFocus until end 2012 BioFocus announced today that the U.S. National Institutes of Health (NIH) have extended their agreement for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) through December 2012. According to the terms of this agreement, BioFocus will be eligible to receive up to $8.6 million (€7.0 million) over the course of the two year extension.

 

  BioFocus renews C.I.R. (French Research Tax Credit) accreditation BioFocus, a leading provider of gene-to-clinical candidate drug discovery services, today announced that it had been notified by the French Ministry of Higher Education and Research, that its CIR accreditation had been renewed.

 

  BioFocus to host free webinar on “unleashing the power of computational chemistry in hit finding campaigns” BioFocus invites drug discovery researchers to join its free webinar entitled ‘unleash the power of computational chemistry in hit finding campaigns', to be held on Thursday 27th May at 15.00 GMT Summer Time. As an educational webinar, attendees will learn how computational chemistry tools enable successful, cost- and time-efficient high-throughput screening (HTS) campaigns.

 

  BioFocus and CHDI Foundation, Inc. enter new five-year collaboration for Huntington’s disease therapeutics BioFocus and CHDI Foundation, Inc., a non-profit virtual biotech pursuing therapies for Huntington's disease, announced today a new five-year collaboration focused on discovering novel drugs for Huntington's disease. BioFocus will perform the research and is eligible to receive US$41 million (€31 million) in research fees during the five-year collaboration.

 

  “Focus on Permeability” - first in a series of free educational webinars for drug discovery researchers, from BioFocus BioFocus invites drug discovery researchers to join its free webinar entitled ‘Focus on permeability'. This educational webinar will guide scientists in the implementation of ADME assays in early drug discovery, and on how best to use the data obtained. Presented by Dr. Alan Beresford, Senior Research Fellow at BioFocus, the webinar will describe commonly used in vitro permeability assays and explain at which stages in the drug discovery process these should be used.

 

  BioFocus launches four compound libraries targeting kinases and protein-protein interactions BioFocus, a leading provider of gene-to-clinical candidate drug discovery services, today announced the launch of four biologically targeted libraries. These new libraries contain novel, drug-like compounds that specifically target kinases and protein-protein interactions.

 

  BioFocus achieves €1.6 M in payments BioFocus announced today that it has achieved success in its oncology target discovery collaboration with Ortho Biotech Oncology Research & Development, a division of Janssen Pharmaceutica N.V. (Janssen). The success of the program has resulted in €1.6 million in target acceptance payments.

 

  TB Alliance and BioFocus sign compound management agreement BioFocus announced today that it has signed a three year compound management agreement with the Global Alliance for TB Drug Development (TB Alliance).

 

  Doris Hafenbradl joins BioFocus as Senior Director, Biology and Natural Products BioFocus, a leading provider of gene-to-drug candidate discovery services, today announced that Dr. Doris Hafenbradl has joined BioFocus as Senior Director, Biology and Natural Products, based in Basel, Switzerland.

 

  BioFocus DPI launches compound library targeting protein-protein interactions plus three new kinase libraries BioFocus DPI, a leading provider of gene-to-drug candidate discovery services, today announced the launch of four new biologically targeted libraries. These new libraries contain novel, drug-like compounds that specifically target kinases and - for the first time - protein-protein interactions.

 

  BioFocus launches new microsite BioFocus has recently launched its new microsite, www.SilenceSelect.com, dedicated to the SilenceSelect® and FLeXSelect® adenoviral technology. With the ability to knock-down or knock-in human genes in primary cells, these collections cover most of the druggable genome.

 

  BioFocus DPI and Procter & Gamble sign compound management agreement BioFocus DPI announced today that it has signed a three year compound management agreement with Procter & Gamble Co. (P&G). Under the agreement, BioFocus DPI will manage P&G’s chemical library collection. These services will be provided by BioFocus DPI’s compound management facility in South San Francisco, USA.

 

  John Nash joins BioFocus as Senior Director, ADME/PK BioFocus, a leading provider of gene-to-drug candidate discovery services, today announced that Dr. John Nash has joined BioFocus as Senior Director, ADME/PK.